Ep 2. Operational Alpha:  Private Equity's Main Lever episode artwork

EPISODE · Jun 17, 2026 · 34 MIN

Ep 2. Operational Alpha: Private Equity's Main Lever

from Operational Velocity · host Gautam Basu

In finance, alpha is the excess return on an investment relative to a benchmark,  the portion of performance that can't be explained by market exposure or beta alone. It's the measure of whether a manager actually outperformed, or simply rode a rising market. For decades, private equity manufactured alpha through cheap leverage and multiple expansion, buy at a discount, add debt, wait for the market to re-rate the asset, sell high. That playbook, which accounted for the majority of buyout returns through 2022, no longer works in a higher-rate, higher-multiple environment.Operational alpha is what's replaced it: excess return generated not by capital structure or market timing, but by improving the fundamental performance of the underlying business — pricing discipline, procurement leverage, supply chain efficiency, commercial strategy, talent productivity. It's alpha built inside the portfolio company, not extracted from the deal structure around it.This episode unpacks why operational alpha has become the primary source of returns left in PE. Buyout IRRs hit a post-2002 trough between 2022 and 2025, while top-quartile funds kept generating 24%, nine points ahead of the S&P 500. The data, from Bain's "12 is the new 5" framework to McKinsey's finding that operationally-focused GPs earn 2–3 points more IRR, points to one conclusion: the firms treating operations as genuine institutional capability are pulling away from the ones still treating it as a line in the pitch deck. We cover where the alpha actually gets made (e.g) procurement, revenue operations, AI-embedded infrastructure and what it means for ETA investors, portfolio company operators, and operations leaders trying to position themselves at the center of value creation, not the periphery of it.Show NotesBuyout fund IRRs: 2022–2025 trough at 5.7% pooled — McKinsey 2026Top-quartile buyout IRR over past decade: 24% vs. S&P 500 at 15%, MSCI World at 13% — McKinsey 202659% of PE returns 2010–2022 came from multiple expansion and leverage — McKinseyPE holding period exceeds 6.7 years — longest since 2005 — McKinsey 202518,000+ unsold PE-backed companies; $3.8tn unrealized value — Bain 2026"12 is the new 5": 10–12% annual EBITDA growth now required for a 2.5x return — Bain 2026GPs focused on operational improvements achieve 2–3 pp higher IRR — McKinsey 100+ fund analysis71% of value creation at exit in 2024 came from revenue growth — Gain.pro 202566% of PE leaders report AI benefits within 12 months, up from 34% prior year — FTI 2026PE firms with formal talent ROI measurement achieve 28% higher returns — PE Operating Excellence ForumBlackstone Portfolio Operations: 500+ professionals, 250 portfolio companies, $226bn revenue, 700k employeesTop-quartile funds derive ~39% of returns from revenue growth and margin expansion vs. 61% from multiples/leverage — McKinsey 2025Sources McKinsey Global Private Markets Report (2026) Bain & Company Global Private Equity Report (2026) FTI Consulting Private Equity Value Creation Index (2026)KPMG "Value Creation in Private Equity" (2025)PwC Private Equity: US Deals Outlook (2026)Bain & Company Asia-Pacific Private Equity Report (2025)Value Creation Institute "PE's Compensation Crisis" ( 2026)Gain.pro Private Equity Value Creation Report (2025)Send us Fan MailOperational Velocity is for education and general information only and is not investment, financial, legal, or tax advice, and nothing in it is a recommendation to buy or sell any security. The views expressed are the host's own, the company and figures discussed are drawn from public sources believed reliable but not guaranteed, and you should do your own research and consult a qualified professional before making any decision.

Episode metadata supplied by the publisher feed · Published Jun 17, 2026

Embed this episode

In finance, alpha is the excess return on an investment relative to a benchmark, the portion of performance that can't be explained by market exposure or beta alone. It's the measure of whether a manager actually outperformed, or simply rode a rising market. For decades, private equity manufactured alpha through cheap leverage and multiple expansion, buy at a discount, add debt, wait for the market to re-rate the asset, sell high. That playbook, which accounted for the majority of buyou...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Ep 2. Operational Alpha: Private Equity's Main Lever

0:00 34:55

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

KaiNexus: Continuous Improvement, Leadership, and More KaiNexus We deliver practical insights and real-world strategies for Lean, Six Sigma, and Operational Excellence. Through lessons from KaiNexus webinars and conversations with customers, improvement leaders, and team members, each episode explores what it takes to build a resilient culture of Continuous Improvement. Learn how organizations engage employees, strengthen problem-solving capability, and sustain meaningful operational results across industries. Whether you're new to CI or leading major transformation, this podcast offers tools and perspectives you can put to work immediately. Global Trial Accelerators™: Fast-Tracking First-in-Human Trials, Anywhere Julio G. Martinez-Clark Hosted by bioaccess® CEO, Julio G. Martinez-Clark, the Global Trial Accelerators™ podcast delivers actionable insights for Medtech, Biopharma, and Radiopharma innovators battling lengthy timelines and costly delays. Each episode features candid conversations with clinical trial pioneers, regulatory strategists, and startup founders who’ve slashed 6–12 months off approvals by leveraging emerging regions like Latin America, Eastern Europe, and Australia.What You’ll Learn:Speed Secrets: How to secure ethics approval in 4–6 weeks (vs. 6+ months in US/EU) using harmonized pathways like MINSA (Panama), ALIMS (Serbia), and Australia’s CTN.Cost-to-Speed Hacks: Operational strategies to reduce trial budgets by 30% while maintaining FDA/EMA compliance.Global Patient Access: Leverage treatment-naive populations in cardiology, rare diseases, and advanced therapies across 50+ pre-vetted sites.Why Listen?<ul

Frequently Asked Questions

How long is this episode of Operational Velocity?

This episode is 34 minutes long.

When was this Operational Velocity episode published?

This episode was published on June 17, 2026.

Can I download this Operational Velocity episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!